Sun Pharmaceuticals Industries announced that the Company's wholly owned U.S. subsidiary presented data from two pivotal Phase 3 clinical trials of WINLEVI (clascoterone) cream 1% for the topical treatment of acne vulgaris (acne). The results, which showed favorable safety and efficacy data in patients 12 years of age and older with acne, were reported today in a poster podium presentation at the American Academy of Dermatology (AAD) 2022 Annual Meeting in Boston, Massachusetts.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
